Scientific publications

November 2023
CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer – Poster Number: 1361
SITC Poster
November 2023
PYX-102, an Anti-KLRG1 Antibody, Enhances Cytotoxic Activity of CD8 T cells from PBMC and Human Tumor Samples by Blocking the Interaction Between KLRG1 and Cadherins Poster Number: 572
SITC Poster
November 2023
First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of anti Siglec-15 PYX-106 in Subjects with Advanced Solid Tumors Poster Number: 756
SITC Poster
November 2023
A First-in-Human Phase 1 Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of the EDB+FN targeting ADC PYX-201 in Participants with Advanced Solid Tumors Poster Number: 762
SITC Poster
September 2023
Quantitation of total antibody (tAb) from antibody drug conjugate (ADC) PYX-201 in rat and monkey plasma using an enzyme-linked immunosorbent assay (ELISA) and its application in preclinical studies (J Pharm Biomed Anal 2023 Sep 5:233:115452.)
Article
August 2023
Development and validation of a hybrid immunoaffinity LC–MS/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma (J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Aug 1:1228:123844.)
Article
July 2023
A sensitive and rapid LC-MS/MS assay for quantitation of free payload Aur0101 from antibody drug conjugate (ADC) PYX-201 in human plasma (J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jul 15:1226:123786.)
Article
July 2023
A sensitive LC–MS/MS assay to quantitate free payload Aur0101 from ADC PYX-201 in rat and monkey plasma (Bioanalysis. 2023 Jul;15(14):833-843.)
Article
June 2023
A Phase 2 Trial with a Safety Lead-in to Evaluate the Addition of Sotigalimab, a CD40 Agonistic Monoclonal Antibody, to Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcoma
ASCO Poster
May 2023
Bioanalysis of an antibody drug conjugate (ADC) PYX-201 in human plasma using a hybrid immunoaffinity LC–MS/MS approach (J Chromatogr B Analyt Technol Biomed Life Sci. 2023 May 15:1223:123715.)
Article